Current challenges and future trends in manufacturing small diameter artificial vascular grafts in bioreactors.
Farid JafarihaghighiMehdi ArdjmandAbolfazl MirzadehMohammad Salar HassaniShahriar Salemi PariziPublished in: Cell and tissue banking (2020)
Cardiovascular diseases are a leading cause of death. Vascular surgery is mainly used to solve this problem. However, the generation of a functional and suitable substitute for small diameter (<ā6 mm) displacement is challengeable. Moreover, synthetic prostheses, made of polyethylene terephthalate and extended polytetrafluoroethylene show have shown insufficient performance. Therefore, the challenges dominating the use of autografts have prevented their efficient use. Tissue engineering is highlighted in regenerative medicine perhaps in aiming to address the issue of end-stage organ failure. While organs and complex tissues require the vascular supply to support the graft survival and render the bioartificial organ role, vascular tissue engineering has shown to be a hopeful method for cell implantation by the production of tissues in vitro. Bioreactors are a salient point in vascular tissue engineering due to the capability for reproducible and controlled variations showing a new horizon in blood vessel substitution. This review strives to display the overview of current concepts in the development of small-diameter by using bioreactors. In this work, we show a critical look at different factors for developing small-diameter and give suggestions for future studies.
Keyphrases
- tissue engineering
- cardiovascular disease
- optic nerve
- wastewater treatment
- type diabetes
- minimally invasive
- current status
- stem cells
- single cell
- coronary artery bypass
- cell therapy
- metabolic syndrome
- coronary artery disease
- percutaneous coronary intervention
- cardiovascular events
- optical coherence tomography
- cardiovascular risk factors